Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology

(RTTNews) - SOPHiA GENETICS (SOPH) and Myriad Genetics, Inc. (MYGN) announced Thursday a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (AZN).

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Source: nasdaq.com

Read the original at nasdaq.com →

Report a problem with this story

More in Health & Medicine

More from Thursday 8 October →